

Pr Gerald Raverot

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6949312/publications.pdf>

Version: 2024-02-01

152
papers

8,134
citations

57681

46
h-index

62345

84
g-index

160
all docs

160
docs citations

160
times ranked

5726
citing authors

#	ARTICLE	IF	CITATIONS
1	Pituitary Society Delphi Survey: An international perspective on endocrine management of patients undergoing transsphenoidal surgery for pituitary adenomas. <i>Pituitary</i> , 2022, 25, 64-73.	1.6	7
2	Postoperative remission of non-invasive lactotroph pituitary tumor: A single-center experience. <i>Annales D'Endocrinologie</i> , 2022, 83, 1-8.	0.6	5
3	First Case of Chronic Post-Traumatic Anterior Pituitary Dysfunction in a Professional Rugby Player: A Case Report. <i>Annales D'Endocrinologie</i> , 2022, , .	0.6	0
4	Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 102-111.	5.5	23
5	Intratumoural spatial distribution of S100 β and folliculostellate cells is associated with proliferation and expression of FSH and ER α in gonadotroph tumours. <i>Acta Neuropathologica Communications</i> , 2022, 10, 18.	2.4	5
6	Clinical Biology of the Pituitary Adenoma. <i>Endocrine Reviews</i> , 2022, 43, 1003-1037.	8.9	81
7	Consensus statement by the French Society of Endocrinology (SFE) and French Society of Pediatric Endocrinology & Diabetology (SFEDP) on diagnosis of Cushing's syndrome. <i>Annales D'Endocrinologie</i> , 2022, 83, 119-141.	0.6	23
8	Identification of predictive criteria for pathogenic variants of primary bilateral macronodular adrenal hyperplasia (PBMAH) gene <i>ARMC5</i> in 352 unselected patients. <i>European Journal of Endocrinology</i> , 2022, 187, 123-134.	1.9	18
9	Immunotherapy in aggressive pituitary tumors and carcinomas: a systematic review. <i>Endocrine-Related Cancer</i> , 2022, 29, 415-426.	1.6	20
10	Pituitary MRI Features in Acromegaly Resulting From Ectopic GHRH Secretion From a Neuroendocrine Tumor: Analysis of 30 Cases. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e3313-e3320.	1.8	7
11	Aggressive corticotroph tumors and carcinomas. <i>Journal of Neuroendocrinology</i> , 2022, 34, .	1.2	20
12	Second line treatment of acromegaly: Pasireotide or Pegvisomant?. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2022, 36, 101684.	2.2	11
13	Prolactin immunoassay: does the high-dose hook effect still exist?. <i>Pituitary</i> , 2022, 25, 653-657.	1.6	10
14	Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study. <i>Endocrine</i> , 2021, 71, 158-167.	1.1	8
15	A key role for conservative treatment in the management of pituitary apoplexy. <i>Endocrine</i> , 2021, 71, 168-177.	1.1	7
16	Management of aggressive pituitary tumors. , 2021, , 485-497.		0
17	Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?. <i>Journal of the Endocrine Society</i> , 2021, 5, bvaa205.	0.1	31
18	Letter to the Editor From Helene Lasolle and Gerald Raverot: α -USP8 and TP53 Drivers Are Associated With CNV in a Corticotroph Adenoma Cohort Enriched for Aggressive Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e3285-e3286.	1.8	1

#	ARTICLE	IF	CITATIONS
19	Graves's Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review). <i>Cancers</i> , 2021, 13, 1944.	1.7	21
20	Pegvisomant treatment in acromegaly in clinical practice: Final results of the French ACROSTUDY (312). <i>Journal of Endocrinology and Investigation</i> , 2021, 14, 106.	0.6	6
21	Aggressive pituitary tumours and pituitary carcinomas. <i>Nature Reviews Endocrinology</i> , 2021, 17, 671-684.	4.3	60
22	Somatostatin receptor ligands induce TSH deficiency in thyrotropin-secreting pituitary adenoma. <i>European Journal of Endocrinology</i> , 2021, 184, 1-8.	1.9	13
23	Cost-Utility of Acromegaly Pharmacological Treatments in a French Context. <i>Frontiers in Endocrinology</i> , 2021, 12, 745843.	1.5	4
24	Aggressive prolactinomas: how to manage?. <i>Pituitary</i> , 2020, 23, 70-77.	1.6	22
25	A Somatostatin Receptor Subtype-3 (SST3) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 957-969.	3.2	34
26	Current status and treatment modalities in metastases to the pituitary: a systematic review. <i>Journal of Neuro-Oncology</i> , 2020, 146, 219-227.	1.4	27
27	Frequency and Incidence of Carney Complex Manifestations: A Prospective Multicenter Study With a Three-Year Follow-Up. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e436-e446.	1.8	30
28	Definition and diagnosis of aggressive pituitary tumors. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2020, 21, 203-208.	2.6	33
29	GNAS mutated thyroid carcinoma in a patient with McCune Albright syndrome. <i>Bone Reports</i> , 2020, 13, 100299.	0.2	6
30	Chromosomal instability in the prediction of pituitary neuroendocrine tumors prognosis. <i>Acta Neuropathologica Communications</i> , 2020, 8, 190.	2.4	20
31	Evaluation of Nurses' and Patients' Overall Satisfaction with New and Previous Formulations of Octreotide Long-acting Release (Sandostatin LAR®): A French Observational Study. <i>Advances in Therapy</i> , 2020, 37, 3901-3915.	1.3	2
32	Treatment Options for Gonadotroph Tumors: Current State and Perspectives. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e3507-e3518.	1.8	15
33	Immune Landscape of Pituitary Tumors Reveals Association Between Macrophages and Gonadotroph Tumor Invasion. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 3459-3473.	1.8	23
34	Immunotherapy in Corticotroph and Lactotroph Aggressive Tumors and Carcinomas: Two Case Reports and a Review of the Literature. <i>Journal of Personalized Medicine</i> , 2020, 10, 88.	1.1	49
35	Anti-PD1 and Anti-PDL1-Induced Hypophysitis: A Cohort Study of 17 Patients with Longitudinal Follow-Up. <i>Journal of Clinical Medicine</i> , 2020, 9, 3280.	1.0	27
36	Metformin and everolimus in neuroendocrine tumours: A synergic effect?. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, 954-960.	0.7	5

#	ARTICLE	IF	CITATIONS
37	Are aggressive pituitary tumors and carcinomas two sides of the same coin? Pathologists reply to clinician's questions. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2020, 21, 243-251.	2.6	30
38	Aggressive Pituitary Adenomas and Carcinomas. <i>Endocrinology and Metabolism Clinics of North America</i> , 2020, 49, 505-515.	1.2	28
39	How to Classify Pituitary Neuroendocrine Tumors (PitNET)s in 2020. <i>Cancers</i> , 2020, 12, 514.	1.7	123
40	Evolution of macroprolactinomas during pregnancy: A cohort study of 85 pregnancies. <i>Clinical Endocrinology</i> , 2020, 92, 421-427.	1.2	9
41	Gonadotroph Tumors Show Subtype Differences that Might Have Implications for Therapy. <i>Cancers</i> , 2020, 12, 1012.	1.7	17
42	Urinary free cortisol: An automated immunoassay without extraction for diagnosis of Cushing's syndrome and follow-up of patients treated by anticortisolic drugs. <i>Clinical Endocrinology</i> , 2020, 93, 76-78.	1.2	4
43	SST5 expression and USP8 mutation in functioning and silent corticotroph pituitary tumors. <i>Endocrine Connections</i> , 2020, 9, 243-253.	0.8	25
44	Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study. <i>European Journal of Endocrinology</i> , 2020, 182, 583.	1.9	36
45	Efficacy and safety of dopamine agonists in patients treated with antipsychotics and presenting a macroprolactinoma. <i>European Journal of Endocrinology</i> , 2020, 183, 221-231.	1.9	8
46	Craniopharyngioma: Endocrinological Aspects After Surgery. , 2020, , 145-156.		1
47	Predicting early post-operative remission in pituitary adenomas: evaluation of the modified knosp classification. <i>Pituitary</i> , 2019, 22, 467-475.	1.6	27
48	Is Gross Total Resection Reasonable in Adults with Craniopharyngiomas with Hypothalamic Involvement?. <i>World Neurosurgery</i> , 2019, 129, e803-e811.	0.7	24
49	Emerging and Novel Treatments for Pituitary Tumors. <i>Journal of Clinical Medicine</i> , 2019, 8, 1107.	1.0	34
50	The Microenvironment of Pituitary Tumors: Biological and Therapeutic Implications. <i>Cancers</i> , 2019, 11, 1605.	1.7	44
51	Illicit Upregulation of Serotonin Signaling Pathway in Adrenals of Patients With High Plasma or Intra-Adrenal ACTH Levels. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 4967-4980.	1.8	15
52	Diagnosis, pathology, and management of TSH-secreting pituitary tumors. A single-center retrospective study of 20 patients from 1981 to 2014. <i>Annales D'Endocrinologie</i> , 2019, 80, 216-224.	0.6	9
53	Ommaya Reservoir System for the Treatment of Cystic Craniopharyngiomas: Surgical Results in a Series of 11 Adult Patients and Review of the Literature. <i>World Neurosurgery</i> , 2019, 132, e869-e877.	0.7	29
54	Modern neuro-ophthalmological evaluation of patients with pituitary disorders. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2019, 33, 101279.	2.2	8

#	ARTICLE	IF	CITATIONS
55	Clinical, Pathological, and Molecular Factors of Aggressiveness in Lactotroph Tumours. <i>Neuroendocrinology</i> , 2019, 109, 70-76.	1.2	44
56	Pheochromocytoma, paragangliomas, and pituitary adenoma. <i>Medicine (United States)</i> , 2019, 98, e16594.	0.4	5
57	Classification of Pituitary Neuroendocrine Tumors (PitNets). , 2019, , 176-184.		3
58	Pasireotide: A potential therapeutic alternative for resistant prolactinoma. <i>Annales D'Endocrinologie</i> , 2019, 80, 84-88.	0.6	38
59	Bilateral adrenalectomy in Cushing's disease: Altered long-term quality of life compared to other treatment options. <i>Annales D'Endocrinologie</i> , 2019, 80, 32-37.	0.6	17
60	Signs and symptoms of acromegaly at diagnosis: the physician's and the patient's perspectives in the ACRO-POLIS study. <i>Endocrine</i> , 2019, 63, 120-129.	1.1	51
61	Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs. <i>Frontiers in Endocrinology</i> , 2019, 10, 931.	1.5	21
62	Cabergoline in severe ectopic or occult Cushing's syndrome. <i>European Journal of Endocrinology</i> , 2019, 181, K1-K9.	1.9	8
63	Confirmation of a new therapeutic option for aggressive or dopamine agonist-resistant prolactin pituitary neuroendocrine tumors. <i>European Journal of Endocrinology</i> , 2019, 181, C1-C3.	1.9	20
64	Pathological markers of somatotroph pituitary neuroendocrine tumors predicting the response to medical treatment. <i>Minerva Endocrinologica</i> , 2019, 44, 129-136.	1.7	14
65	Diagnosis and Clinical Management of Aggressive Pituitary Tumors. , 2019, , 294-300.		1
66	Ectopic acromegaly due to growth hormone-releasing hormone producing bronchial carcinoid causing somatotroph hyperplasia and partial pituitary insufficiency. <i>Polish Archives of Internal Medicine</i> , 2019, 129, 208-210.	0.3	4
67	Centralization errors in comparative genomic hybridization array analysis of pituitary tumor samples. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 320-328.	1.5	2
68	Hepatic safety of ketoconazole in Cushing's syndrome: results of a Compassionate Use Programme in France. <i>European Journal of Endocrinology</i> , 2018, 178, 447-458.	1.9	46
69	Aggressive pituitary tumours and carcinomas: two sides of the same coin?. <i>European Journal of Endocrinology</i> , 2018, 178, C7-C9.	1.9	54
70	Physiopathology, Diagnosis, and Treatment of Nonfunctioning Pituitary Adenomas. <i>Endocrinology</i> , 2018, , 93-128.	0.1	1
71	MANAGEMENT OF ENDOCRINE DISEASE Hyperandrogenic states in women: pitfalls in laboratory diagnosis. <i>European Journal of Endocrinology</i> , 2018, 178, R141-R154.	1.9	19
72	Prognostic factors of regrowth in nonfunctioning pituitary tumors. <i>Pituitary</i> , 2018, 21, 176-182.	1.6	28

#	ARTICLE	IF	CITATIONS
73	Triple-A syndrome: a wide spectrum of adrenal dysfunction. <i>European Journal of Endocrinology</i> , 2018, 178, 199-207.	1.9	38
74	Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. <i>European Journal of Endocrinology</i> , 2018, 178, 265-276.	1.9	196
75	Dysregulation of cell cycle in animal models and human neuroendocrine pituitary tumors (PitNET). <i>Cell Cycle</i> , 2018, 17, 917-917.	1.3	0
76	European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. <i>European Journal of Endocrinology</i> , 2018, 178, G1-G24.	1.9	387
77	Sex-Related Differences in Lactotroph Tumor Aggressiveness Are Associated With a Specific Gene-Expression Signature and Genome Instability. <i>Frontiers in Endocrinology</i> , 2018, 9, 706.	1.5	40
78	35e Congrès de la Société française d'endocrinologie (SFE) Nancy 2018. <i>Annales D'Endocrinologie</i> , 2018, 79, 191.	0.6	0
79	ALK7 expression in prolactinoma is associated with reduced prolactin and increased proliferation. <i>Endocrine-Related Cancer</i> , 2018, 25, 795-806.	1.6	10
80	Unusual neurologic presentation of aseptic abscesses syndrome. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e469.	3.1	1
81	Physiopathology, Diagnosis, and Treatment of Nonfunctioning Pituitary Adenomas. <i>Endocrinology</i> , 2018, , 1-37.	0.1	0
82	MicroRNAs in pituitary tumors. <i>Molecular and Cellular Endocrinology</i> , 2017, 456, 51-61.	1.6	39
83	From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. <i>Endocrine-Related Cancer</i> , 2017, 24, C5-C8.	1.6	262
84	Transdifferentiation of Neuroendocrine Cells. <i>American Journal of Surgical Pathology</i> , 2017, 41, 849-853.	2.1	19
85	Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas. <i>European Journal of Endocrinology</i> , 2017, 176, 769-777.	1.9	107
86	Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A Pituitary Society Statement. <i>Pituitary</i> , 2017, 20, 489-498.	1.6	233
87	Reconsidering olfactory bulb magnetic resonance patterns in Kallmann syndrome. <i>Annales D'Endocrinologie</i> , 2017, 78, 455-461.	0.6	7
88	Risk of Recurrence in Pituitary Neuroendocrine Tumors: A Prospective Study Using a Five-Tiered Classification. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 3368-3374.	1.8	112
89	Risks and Benefits of Endoscopic Transsphenoidal Surgery for Nonfunctioning Pituitary Adenomas in Patients of the Ninth Decade. <i>World Neurosurgery</i> , 2017, 106, 315-321.	0.7	14
90	Silent somatotroph tumour revisited from a study of 80 patients with and without acromegaly and a review of the literature. <i>European Journal of Endocrinology</i> , 2017, 176, 195-201.	1.9	33

#	ARTICLE	IF	CITATIONS
91	An old retrocardiac mass fortuitously reclassified as paraganglioma. <i>Annales D'Endocrinologie</i> , 2016, 77, 668-669.	0.6	0
92	Therapeutic innovations in endocrine diseases – part 3: temozolomide and future therapeutics for aggressive pituitary tumors and carcinomas. <i>Presse Medicale</i> , 2016, 45, e211-e216.	0.8	9
93	Performance of the 4-mg intravenous dexamethasone suppression test in differentiating Cushing disease from pseudo-Cushing syndrome. <i>Annales D'Endocrinologie</i> , 2016, 77, 30-36.	0.6	7
94	Establishment of revised diagnostic cut-offs for adrenal laboratory investigation using the new Roche Diagnostics Elecsys® Cortisol II assay. <i>Annales D'Endocrinologie</i> , 2016, 77, 620-622.	0.6	39
95	T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly. <i>Endocrine-Related Cancer</i> , 2016, 23, 871-881.	1.6	82
96	Differential Effects of PI3K and Dual PI3K/mTOR Inhibition in Rat Prolactin-Secreting Pituitary Tumors. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1261-1270.	1.9	19
97	Dramatic change in skin color after bilateral adrenalectomy in Cushing's disease. <i>Annales D'Endocrinologie</i> , 2016, 77, 623-624.	0.6	0
98	Pituitary siderosis: the dark side of the pituitary. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 374.	5.5	2
99	Clinicopathological prognostic and theranostic markers in pituitary tumors. <i>Minerva Endocrinologica</i> , 2016, 41, 377-89.	1.7	12
100	Pituitary Involvement in Granulomatosis With Polyangiitis. <i>Medicine (United States)</i> , 2015, 94, e748.	0.4	61
101	Dilated Cardiomyopathy Revealing Cushing Disease. <i>Medicine (United States)</i> , 2015, 94, e2011.	0.4	16
102	Deregulation of miR-183 and KIAA0101 in Aggressive and Malignant Pituitary Tumors. <i>Frontiers in Medicine</i> , 2015, 2, 54.	1.2	33
103	Expression of estrogen receptor alpha is associated with prolactin pituitary tumor prognosis and supports the sex-related difference in tumor growth. <i>European Journal of Endocrinology</i> , 2015, 172, 791-801.	1.9	76
104	A Prognostic Clinicopathologic Classification of Pituitary Endocrine Tumors. <i>Endocrinology and Metabolism Clinics of North America</i> , 2015, 44, 11-18.	1.2	29
105	Pituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences. <i>Endocrine-Related Cancer</i> , 2015, 22, 169-177.	1.6	78
106	Biological and radiological exploration and management of non-functioning pituitary adenoma. <i>Annales D'Endocrinologie</i> , 2015, 76, 201-209.	0.6	25
107	Macroprolactinaemia: a biological diagnostic strategy from the study of 222 patients. <i>European Journal of Endocrinology</i> , 2015, 172, 687-695.	1.9	9
108	Downregulation of miR-410 targeting the cyclin B1 gene plays a role in pituitary gonadotroph tumors. <i>Cell Cycle</i> , 2015, 14, 2590-2597.	1.3	46

#	ARTICLE	IF	CITATIONS
109	Management of clinically non-functioning pituitary adenoma. <i>Annales D'Endocrinologie</i> , 2015, 76, 239-247.	0.6	136
110	<i>HMGA1</i> -pseudogene expression is induced in human pituitary tumors. <i>Cell Cycle</i> , 2015, 14, 1471-1475.	1.3	48
111	Macroprolactinomas in Children and Adolescents: Factors Associated With the Response to Treatment in 77 Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 1177-1186.	1.8	83
112	MANAGEMENT OF ENDOCRINE DISEASE: Clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies. <i>European Journal of Endocrinology</i> , 2014, 170, R121-R132.	1.9	81
113	Expression of somatostatin receptors, SSTR2A and SSTR5, in 108 endocrine pituitary tumors using immunohistochemical detection with new specific monoclonal antibodies. <i>Human Pathology</i> , 2014, 45, 71-77.	1.1	79
114	Ketoconazole in Cushing's Disease: Is It Worth a Try?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 1623-1630.	1.8	231
115	Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 875-884.	5.5	309
116	Giant prolactinomas in women. <i>European Journal of Endocrinology</i> , 2014, 170, 31-38.	1.9	64
117	miR-23b and miR-130b expression is downregulated in pituitary adenomas. <i>Molecular and Cellular Endocrinology</i> , 2014, 390, 1-7.	1.6	78
118	Non-functioning pituitary macro-incidentomas benefit from early surgery before becoming symptomatic. <i>Clinical Neurology and Neurosurgery</i> , 2013, 115, 2514-2520.	0.6	25
119	Silent GH pituitary tumor: Diagnostic and therapeutic challenges. <i>Annales D'Endocrinologie</i> , 2013, 74, 491-495.	0.6	15
120	A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. <i>Acta Neuropathologica</i> , 2013, 126, 123-135.	3.9	395
121	Aggressive Silent GH Pituitary Tumor Resistant to Multiple Treatments, Including Temozolomide. <i>Cancer Investigation</i> , 2013, 31, 190-196.	0.6	32
122	¹⁸ F-FDG PET/CT Findings in a Patient With Isolated Intracranial Rosai-Dorfman Disease. <i>Clinical Nuclear Medicine</i> , 2013, 38, e50-e52.	0.7	17
123	Altered MicroRNA Expression Profile in Human Pituitary GH Adenomas: Down-Regulation of miRNA Targeting <i>HMGA1</i> , <i>HMGA2</i> , and <i>E2F1</i> . <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E1128-E1138.	1.8	136
124	Hypothalamo-pituitary sarcoidosis: a multicenter study of 24 patients. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2012, 105, 981-995.	0.2	116
125	Clinical Characteristics and Outcome of Acromegaly Induced by Ectopic Secretion of Growth Hormone-Releasing Hormone (GHRH): A French Nationwide Series of 21 Cases. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 2093-2104.	1.8	81
126	Acromegaly induced by ectopic secretion of GHRH: A review 30 years after GHRH discovery. <i>Annales D'Endocrinologie</i> , 2012, 73, 497-502.	0.6	64

#	ARTICLE	IF	CITATIONS
127	Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. <i>Clinical Endocrinology</i> , 2012, 76, 769-775.	1.2	125
128	New targeted therapies in pituitary carcinoma resistant to temozolomide. <i>Pituitary</i> , 2012, 15, 37-43.	1.6	87
129	Integrated Genomic Profiling Identifies Loss of Chromosome 11p Impacting Transcriptomic Activity in Aggressive Pituitary PRL Tumors. <i>Brain Pathology</i> , 2011, 21, 533-543.	2.1	46
130	Evidence of improved surgical outcome following endoscopy for nonfunctioning pituitary adenoma removal. <i>Neurosurgical Focus</i> , 2011, 30, E11.	1.0	126
131	Ectopic ACTH Syndrome in Children and Adolescents. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 1213-1222.	1.8	63
132	Integrated Genomic Profiling Identifies Loss of Chromosome 11p Impacting Transcriptomic Activity in Aggressive Pituitary PRL Tumours. , 2011, , P3-69-P3-69.		0
133	Cabergoline therapy of paraneoplastic cushing syndrome in children. <i>Pediatric Blood and Cancer</i> , 2010, 55, 590-591.	0.8	3
134	Clinical Characteristics and Therapeutic Responses in Patients with Germ-Line <i>AIP</i> Mutations and Pituitary Adenomas: An International Collaborative Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, E373-E383.	1.8	323
135	Clinical, hormonal and molecular characterization of pituitary ACTH adenomas without (silent) Tj ETQq1 1 0.784314 rgBT /Overlock 1 35-43.	1.9	94
136	Carcinome hypophysaire. , 2010, , 441-445.		2
137	Prognostic Factors in Prolactin Pituitary Tumors: Clinical, Histological, and Molecular Data from a Series of 94 Patients with a Long Postoperative Follow-Up. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 1708-1716.	1.8	144
138	Temozolomide Treatment in Aggressive Pituitary Tumors and Pituitary Carcinomas: A French Multicenter Experience. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 4592-4599.	1.8	202
139	Sex hormone-binding globulin gene expression in the liver: Drugs and the metabolic syndrome. <i>Molecular and Cellular Endocrinology</i> , 2010, 316, 53-59.	1.6	100
140	Proliferation markers of human pituitary tumors: Contribution of a genome-wide transcriptome approach. <i>Molecular and Cellular Endocrinology</i> , 2010, 326, 30-39.	1.6	27
141	Secondary deterioration of visual field during cabergoline treatment for macroprolactinoma. <i>Clinical Endocrinology</i> , 2009, 70, 588-592.	1.2	42
142	Predicting Visual Outcome After Treatment of Pituitary Adenomas With Optical Coherence Tomography. <i>American Journal of Ophthalmology</i> , 2009, 147, 64-70.e2.	1.7	135
143	Aryl Hydrocarbon Receptor-Interacting Protein Gene Mutations in Familial Isolated Pituitary Adenomas: Analysis in 73 Families. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 1891-1896.	1.8	283
144	Familial pituitary adenomas with a heterogeneous functional pattern: Clinical and genetic features. <i>Journal of Endocrinological Investigation</i> , 2007, 30, 787-790.	1.8	5

#	ARTICLE	IF	CITATIONS
145	A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors. <i>Endocrine-Related Cancer</i> , 2007, 14, 887-900.	1.6	146
146	Mitotane Has an Estrogenic Effect on Sex Hormone-Binding Globulin and Corticosteroid-Binding Globulin in Humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 2165-2170.	1.8	75
147	Sox3 expression in undifferentiated spermatogonia is required for the progression of spermatogenesis. <i>Developmental Biology</i> , 2005, 283, 215-225.	0.9	142
148	Nuclear receptors Sf1 and Dax1 function cooperatively to mediate somatic cell differentiation during testis development. <i>Development (Cambridge)</i> , 2005, 132, 2415-2423.	1.2	81
149	Influence of SHBG Gene Pentanucleotide TAAA Repeat and D327N Polymorphism on Serum Sex Hormone-Binding Globulin Concentration in Hirsute Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 917-924.	1.8	109
150	X-Linked Sex-Determining Region Y Box 3 (SOX3) Gene Mutations Are Uncommon in Men with Idiopathic Oligozoospermic Infertility. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 4146-4148.	1.8	19
151	Sox3 Is Required for Gonadal Function, but Not Sex Determination, in Males and Females. <i>Molecular and Cellular Biology</i> , 2003, 23, 8084-8091.	1.1	168
152	Neoadjuvant B-RAF and MEK Inhibitor Targeted Therapy for Adult Papillary Craniopharyngiomas: A New Treatment Paradigm. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	14